July 24, 2024:
Daniel Isaac, DO, an Assistant Professor in the Division of Hematology and Oncology at Michigan State University College of Human Medicine, has been appointed to represent Michigan State University on the Big Ten Cancer Research Consortium Steering Committee.
July 23, 2024:
The Big Ten Cancer Research Consortium (Big Ten CRC) Population Science Clinical Trial Working Group has received $5,000 of a $90,000 donation to be used for collaborative research regarding rural cancer survivorship. The donation is the second given to the Big Ten CRC by the Verna Mae Jessen Trust, with the first donation of $100,000 given in 2022.
Rural cancer survivors are at risk for poorer physical, social, and psychological outcomes than non-rural cancer survivors. According to Sharon Manne, PhD, (pictured left) of Rutgers Cancer Institute and Electra Paskett, PhD, (pictured right) of The Ohio State University Wexner Medical Center, co-chairs of the Population Science working group, this collaborative research aims to examine survivorship experiences across rural populations in Big Ten states, including Ohio, Nebraska, Wisconsin, and Indiana.
The goal is to describe the social and psychological outcomes of cancer survivors who reside in the catchment areas of the Big Ten CRC Cancer Centers in these states, identify sociodemographic and medical factors that have significant impact, and characterize disparities between rural and non-rural cancer survivors.
The research will provide valuable insights into the unique challenges faced by rural cancer survivors and inform strategies to address disparities in their outcomes.
The Population Science working group will be presenting at the Big Ten CRC Summit. Learn more about the summit and register to attend at https://bigtencrc.org/summit/.
The Verna Mae Jessen Trust supports nonprofit organizations working in cancer or pain management research. The Jessen family’s passion for oncology research stems from their long history with cancer. Several members of the family, including Kenneth, Verna Mae, and two of their siblings fought battles with cancer.
“Our family recognizes the great strides already made and the importance of continuing to fund cancer research,” said Tom Jensen, nephew of Kenneth and Verna Mae Jessen and administrator of the Verna Mae Jessen Trust.
About the Big Ten Cancer Research Consortium: The Big Ten Cancer Research Consortium was created in 2013 to transform the conduct of cancer research through collaborative clinical trials and observational studies that seek to improve the lives of cancer patients in the diverse communities we serve by leveraging the scientific and clinical expertise of Big Ten universities. The Big Ten Cancer Research Consortium creates a unique team research culture to drive science rapidly from ideas to treatment and prevention. Within this innovative environment, today’s research leaders collaborate with and mentor the research leaders of tomorrow. Since its founding, the Big Ten CRC has activated nearly 40 clinical trials across a wide range of cancer types, more than 1,000 participants have enrolled in Big Ten CRC studies, and more than 500 researchers have joined Big Ten CRC Clinical Trial Working Groups.
About the Big Ten Conference: The Big Ten Conference is an association of world-class universities whose member institutions share a common mission of research, graduate, professional and undergraduate teaching and public service. Founded in 1896, the Big Ten has sustained a comprehensive set of shared practices and policies that enforce the priority of academics in the lives of students competing in intercollegiate athletics and emphasize the values of integrity, fairness and competitiveness. The broad-based programs of the 14 Big Ten institutions will provide over $200 million in direct financial support to more than 9,800 students for more than 11,000 participation opportunities on 350 teams in 42 different sports. The Big Ten sponsors 28 official conference sports, 14 for men and 14 for women, including the addition of men’s ice hockey and men’s and women’s lacrosse since 2013. For more information, visit www.bigten.org.
July 15, 2024:
The Big Ten Cancer Research Consortium has launched new episodes for each of our podcast series: “Bridging the Gap” and “AYA Cancer in Focus.”
The most recent episode of “Bridging the Gap” is titled, “Patient perspective: A Black woman’s personal experience regarding clinical trial treatment.” In this episode, Dr. Coral Omene from Rutgers Cancer Institute of New Jersey talks with Tina Butts, a breast cancer survivor, about her experiences as a Black female patient in a clinical trial. It is an illuminating and touching conversation about resilience, faith, and the emotional realities of life with cancer. Listen to the full episode: https://player.captivate.fm/episode/27d862a0-952c-4c72-90c8-92a2e2f32b10
The most recent episode of “AYA Cancer in Focus” is titled, “Adolescent and Young Adult Cancer Research and Survivorship: Helaina’s Story.” In this episode, Dr. David Dickens from the University of Iowa Holden Comprehensive Cancer Center talks with Helaina Hillyard, an adolescent and young adult (AYA) cancer survivor, about her experiences. Helaina and Dr. Dickens share a heartfelt conversation about hope, resilience, and the realities of navigating life with cancer. Listen to the full episode: https://player.captivate.fm/episode/acd39559-3a0a-42f5-863a-06baf69818d6
Listen to previous episodes here:
About the Big Ten Cancer Research Consortium: The Big Ten Cancer Research Consortium was created in 2013 to transform the conduct of cancer research through collaborative clinical trials and observational studies that seek to improve the lives of cancer patients in the diverse communities we serve by leveraging the scientific and clinical expertise of Big Ten universities. The Big Ten Cancer Research Consortium creates a unique team research culture to drive science rapidly from ideas to treatment and prevention. Within this innovative environment, today’s research leaders collaborate with and mentor the research leaders of tomorrow. Since its founding, the Big Ten CRC has activated nearly 40 clinical trials across a wide range of cancer types, more than 1,000 participants have enrolled in Big Ten CRC studies, and more than 500 researchers have joined Big Ten CRC Clinical Trial Working Groups.
About the Big Ten Conference: The Big Ten Conference is an association of world-class universities whose member institutions share a common mission of research, graduate, professional and undergraduate teaching and public service. Founded in 1896, the Big Ten has sustained a comprehensive set of shared practices and policies that enforce the priority of academics in the lives of students competing in intercollegiate athletics and emphasize the values of integrity, fairness and competitiveness. The broad-based programs of the 14 Big Ten institutions will provide over $200 million in direct financial support to more than 9,800 students for more than 11,000 participation opportunities on 350 teams in 42 different sports. The Big Ten sponsors 28 official conference sports, 14 for men and 14 for women, including the addition of men’s ice hockey and men’s and women’s lacrosse since 2013. For more information, visit www.bigten.org.
July 12, 2024:
Mark Burkard, MD, PhD, has been named director of Holden Comprehensive Cancer Center at the University of Iowa, and will begin his new role on October 1, pending approval from the Iowa Board of Regents. He will also begin as professor in the Department of Internal Medicine in the Division of Hematology, Oncology, and Blood Marrow Transplantation in the Carver College of Medicine.
May 29, 2024:
A Big Ten Cancer Research Consortium (Big Ten CRC) study was published in Nature Communications on February 1, 2024. The article is titled, “Durvalumab and guadecitabine in advanced clear cell renal cell carcinoma: results from the phase Ib/II study BTCRC-GU16-043.”
May 28, 2024:
Monika Joshi, MD, MRCP, has been re-appointed as the chief scientific officer of the Big Ten Cancer Research Consortium.
May 15, 2024:
The Big Ten Cancer Research Consortium (Big Ten CRC) is set to participate in the American Society of Clinical Oncology® (ASCO) 2024 Annual Meeting in Chicago from May 31 to June 4. During the event, three Big Ten CRC studies will be presented, working group meetings will take place, and the Big Ten CRC will host a joint reception with Hoosier Cancer Research Network (HCRN). The Big Ten CRC will also be represented in the exhibit hall at HCRN’s booth, #37113.
May 9, 2024:
Raymond J. Hohl, MD, PhD, was recently named chair of the Cancer Center Directors Committee for the Big Ten Cancer Research Consortium (Big Ten CRC). In this role, Dr. Hohl will help guide strategic priorities for the Big Ten CRC as the consortium enters its second decade. Dr. Hohl has been a member of the leadership committee since the consortium’s founding in 2013 and succeeds Howard Bailey, MD, director of the University of Wisconsin Carbone Cancer Center, as the committee chair. Read More
May 7, 2024:
The Big Ten Cancer Research Consortium (Big Ten CRC) recently appointed Oana Danciu, MD, as chair of the consortium’s steering committee. Dr. Danciu is associate director of clinical research at the University of Illinois Cancer Center, a breast oncologist at UI Health, and associate professor in the Division of Hematology and Oncology at the University of Illinois College of Medicine Chicago. She succeeds Vijaya Raj Bhatt, MBBS, MS, of the University of Nebraska Medical Center, as chair of the committee. Read More
May 3, 2024:
The Big Ten Cancer Research Consortium (Big Ten CRC) is excited to announce the release of a new public service announcement (PSA), showcasing the importance of scientific research collaboration among the Big Ten Cancer Centers. This PSA appears on the Big Ten Network.
© 2024 All rights reserved.
Big Ten Cancer Research Consortium
7676 Interactive Way, Suite 120, Indianapolis, IN 46278
Subscribe to the Big Ten CRC Newsletter
X
Facebook
YouTube